Vertex Pharmaceuticals’ Revenue Forecast Tops Expectations | Global News Avenue

Vertex Pharmaceuticals(VRTX) reported fourth-quarter revenue and provided 2025 outlook, which exceeded analyst expectations.

The company said it expects revenues of $11.75 billion to $12 billion in 2025, up nearly 20% in 2024, well above the visible Alpha compiled analyst forecast.

Vertex’s fourth-quarter revenue was $2.91 billion, up 16% year-on-year, also surpassing analyst consensus. Adjusted revenue was $1.04 billion, or $3.98 per share, down slightly above estimates from $1.1 billion or $4.20 per share a year ago. The Pinpoint pointed out that operating expenses are increased, interest income is lower, and lower tax expenses are higher.

The result is Food and Drug Administration Recently approved Vertex Pharmaceuticals’ Non-opioid painkiller Journavxtwice a day for acute pain. CEO Reshma Kewalramani called Journavx “the first new painkiller approved in more than 20 years”.

After the issuance, Vertex Pharmaceuticals shares have little change in the expanded trading on Monday. The stock has risen 12% by the end of Monday in the past 12 months.